KLAS: Providers say electronic order sets have greatest CDS impact

Although providers can use a variety of tools to improve electronic clinical decision support (CDS), 38 percent indicated that electronic order sets are having the greatest impact on their organization, according to a new KLAS report.

Evidence-based alerts and reference content were also mentioned as most impactful by 19 percent and 10 percent of providers, respectively, the Orem, Utah market researcher stated.

The report, “Clinical Decision Support: Striving for More Intelligent Care,” details provider CDS activity in five areas: order sets, multi-parameter alerting, nursing care plans, reference content and drug information databases. The report also highlights third-party (non-EMR) vendors that providers are turning to for help with CDS content development and integration.

Providers were most likely to turn to a third party for drug information databases, reference content, and order sets, and least likely to use an outside vendor for multi-parameter alerting, the survey found. Those that used third-party content for order sets reported varying levels of difficulty integrating that content into their core clinical system.

Many providers are focusing primarily on meeting meaningful use Stage 1 CDS requirements, and don’t have clear CDS plans beyond Stage 1. Among vendors cited in the survey, Zynx Health and ProVation were being used most often for order sets; UpToDate, MD Consult and DynaMed for reference content, Zynx Health and CPMRC for nursing care plans; and Multum, FirstDataBank, Micromedex and Lexi-Comp for drug information databases.

The full report is available for purchase here.

Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.